



Contact:

Douglas Doerfler
President and CEO
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

MaxCyte to Be Featured at the BioDevice Partnering 2006

Gaithersburg, MD, June 13, 2006 – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announces Douglas A. Doerfler, President and CEO, will be presenting at the BioDevice Partnering Conference in Edinburgh, Scotland, Sheraton Grand Hotel & Spa, on Tuesday, June 13th, 2006 at 4:30 PM on Level 2, Melville Suite.

Mr. Doerfler will provide a brief corporate overview and discuss the company's preclinical and clinical product candidates, partnering activities, and enabling technology for therapeutic development and biotherapeutic manufacturing.

About MaxCyte

MaxCyte Inc. is a clinical stage company developing cell-based therapeutics primarily in the areas of oncology and regenerative medicine. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. The company also offers its unparalleled, customizable flow based cell loading technology to partners who take advantage of its advanced capabilities for cell-based therapeutic development and biotherapeutic (viral vector) manufacturing through licensing relationships. Partners are currently working to develop therapeutics for pulmonary, cardiovascular and infectious disease, cancer and regenerative medicine.

For more information, visit <http://www.maxcyte.com>.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###